Author:
Ramos-Casals Manuel,Brito-Zerón Pilar,Cuadrado Maria-Jose,Khamashta Munther A.
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Haraoui B: Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005, 34:7–11.
2. Nurmohamed MT, Dijkmans BA: Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005, 65:661–694.
3. Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275–2285.
4. Genovese MC, Bathon JM, Fleischmann RM, et al.: Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005, 32:1232–1242.
5. Lebwohl M, Gottlieb A, Wallis W, Zitnik R: Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. J Am Acad Dermatol 2005, 52:195.
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献